Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Repurchased
Ratios

Ligand Pharmaceuticals (LGND) Receivables Refunds (2018 - 2025)

Ligand Pharmaceuticals' Receivables Refunds history spans 9 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Receivables Refunds fell 64.5% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, down 64.5%, while the annual FY2025 figure was $1.4 million, 64.5% down from the prior year.
  • Receivables Refunds for Q4 2025 was $1.4 million at Ligand Pharmaceuticals, up from $536000.0 in the prior quarter.
  • Across five years, Receivables Refunds topped out at $7.8 million in Q3 2024 and bottomed at $536000.0 in Q3 2025.
  • The 5-year median for Receivables Refunds is $4.2 million (2024), against an average of $3.6 million.
  • The largest annual shift saw Receivables Refunds soared 179.34% in 2021 before it crashed 93.14% in 2025.
  • A 5-year view of Receivables Refunds shows it stood at $6.2 million in 2021, then decreased by 25.5% to $4.6 million in 2022, then soared by 38.6% to $6.4 million in 2023, then crashed by 36.31% to $4.1 million in 2024, then crashed by 64.5% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Receivables Refunds are $1.4 million (Q4 2025), $536000.0 (Q3 2025), and $828000.0 (Q2 2025).